GlassScriptPhysician profile
Jay Babu Patel
NPI 1093176992
$1,732.31
in general payments reported to CMS, 2019-2025
19 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $261 · 2021: $132 · 2022: $439 · 2023: $381 · 2024: $105 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $292.53 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $242.37 | 2019-2022 | |
| Pfizer INC. | $216.08 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $200.33 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.12 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $119.61 | 2020-2025 | Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $83.34 | 2019-2023 | |
| Abbott Laboratories | $63.69 | 2021-2022 | |
| Novo Nordisk INC | $30.50 | 2022 | |
| Vifor Pharma, INC. | $29.78 | 2019-2020 | |
| Gilead Sciences, INC. | $29.28 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.80 | 2025 | Lifevest |
| Mallinckrodt Hospital Products INC. | $21.30 | 2023 | Terlivaz |
| Mallinckrodt Enterprises LLC | $20.36 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $20.10 | 2025 | |
| Abbvie INC. | $20.00 | 2019 | |
| Aimmune Therapeutics, INC. | $16.60 | 2024 | |
| Shire North American Group INC | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.